– Inaugural multi-stakeholder event on
June 11th (6/11) will raise
awareness and bring together individuals living with RRP,
caregivers, clinicians, and government officials –
– RRP is a rare, HPV-driven
disease with no FDA-approved therapeutic –
GERMANTOWN, Md., March 28,
2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a
biopharmaceutical company specializing in the development of
innovative gene and cell therapies to improve the lives of
patients, today announced that the Company has teamed up with the
Recurrent Respiratory Papillomatosis Foundation (RRPF) to launch
the first RRP Awareness Day™ on June 11, 2024, a multi-stakeholder event to raise
awareness about recurrent respiratory papillomatosis (RRP) and
bring together RRP patients and their caregivers to encourage new
connections and build community among those interested in and
affected by this devastating disease.
Awareness activities will culminate in an inaugural event on
June 11th featuring a moderated panel
discussion with RRP patients and caregivers, insights from RRP
clinicians, and a policy discussion with government officials. The
inaugural event will be hybrid with both in-person participation at
the Press Club in Washington DC
and a webcast for virtual participation.
"As a patient and an advocate on behalf of the RRP community, I
am thrilled to team up with Precigen to raise awareness about RRP
and bring together critical stakeholders to engage in a dialogue on
important aspects impacting individuals living with RRP," said
Kim McClellan, Board President,
RRPF. "We would like to invite and encourage anyone living with
RRP, either as a patient, family member or caregiver, to join us in
spreading the word about RRP and participate in this event."
"We are incredibly proud to join forces with the RRPF to
establish the first global RRP Awareness Day to bring visibility to
the many challenges experienced by RRP patients and to help forge
connections among patients, clinicians and government officials. At
Precigen, finding new solutions for patients is why we come to work
every day and we are proud of our work to engage the patient
community in designing and progressing our RRP clinical trials. The
RRPF and their robust community have helped us to ensure that the
patient voice is integrated into our RRP program and we look
forward to working together in the years to come to by 'giving
voice to inspire change', our theme for our RRP awareness
activities and our rally cry until there's a readily available cure
for this devastating disease," said Helen
Sabzevari, PhD, President and CEO of Precigen.
RRP is a rare, difficult-to-treat disease of the upper and lower
respiratory tracts that is caused by infection with human
papillomavirus (HPV) 6 or HPV 11. There are no FDA-approved
therapeutics for the treatment of RRP and the current
standard-of-care involves recurring surgeries to remove benign
tumors that repeatedly grow along the respiratory tract. RRP can
cause severe voice disturbance, airway compromise, fatal pulmonary
lesions, and invasive cancers.
To stay up-to-date with RRP Awareness Day activities and to
register for the inaugural event, please visit
www.RRPAwareness.org.
Precigen: Advancing Medicine with
Precision™
Precigen (Nasdaq: PGEN) is a dedicated
discovery and clinical stage biopharmaceutical company advancing
the next generation of gene and cell therapies using precision
technology to target the most urgent and intractable diseases in
our core therapeutic areas of immuno-oncology, autoimmune
disorders, and infectious diseases. Our technologies enable us to
find innovative solutions for affordable biotherapeutics in a
controlled manner. Precigen operates as an innovation engine
progressing a preclinical and clinical pipeline of
well-differentiated therapies toward clinical proof-of-concept and
commercialization. For more information about Precigen, visit
www.precigen.com or follow us on X @Precigen, LinkedIn or
YouTube.
About RRPF
The Recurrent Respiratory Papillomatosis
Foundation (RRPF) was created to provide family support; promote
public awareness; and aid in the prevention, cure, and treatment of
recurrent respiratory papillomatosis (RRP), a rare disease that
affects the voice. The most common symptoms of RRP are a hoarse or
strained voice, dysphonia (difficulty in speaking), or aphonia
(loss of voice). The organization focuses primarily on networking
within the RRP community, including patients, families, medical
practitioners, and researchers. Its goal is to stimulate more
RRP-related research that may lead to more effective treatments
and, ultimately, a cure for this disease. Professional/consumer
brochures/pamphlets are available.
Trademarks
Precigen, RRP Awareness Day, Recurrent
Respiratory Papillomatosis Awareness Day, RRP Awareness Day Giving
Voice to Inspire Change, and Advancing Medicine with Precision are
trademarks of Precigen and/or its affiliates. Other names
may be trademarks of their respective owners.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon the Company's current expectations and projections
about future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs, product candidate approval and
commercialization and related milestones, the promise of the
Company's portfolio of therapies, and in particular its CAR-T and
AdenoVerse therapies. Although management believes that the plans
and objectives reflected in or suggested by these forward-looking
statements are reasonable, all forward-looking statements involve
risks and uncertainties and actual future results may be materially
different from the plans, objectives and expectations expressed in
this press release. The Company has no obligation to provide any
updates to these forward-looking statements even if its
expectations change. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. For
further information on potential risks and uncertainties, and other
important factors, any of which could cause the Company's actual
results to differ from those contained in the forward-looking
statements, see the section entitled "Risk Factors" in the
Company's most recent Annual Report on Form 10-K and subsequent
reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M.
Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-and-recurrent-respiratory-papillomatosis-foundation-to-hold-inaugural-international-rrp-awareness-day-on-june-11th-302103000.html
SOURCE Precigen, Inc.